...
首页> 外文期刊>Stem Cell Research & Therapy >Differentiation of primordial germ cells from premature ovarian insufficiency-derived induced pluripotent stem cells
【24h】

Differentiation of primordial germ cells from premature ovarian insufficiency-derived induced pluripotent stem cells

机译:来自早产卵巢源性衍生诱导多能干细胞的原始生殖细胞的分化

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Premature ovarian insufficiency (POI) is a common disease in reproductive women. The pathogenesis of POI is not clear, although it is known that it involves the disorder of oocyte differentiation and development. The introduction of reprogramming human somatic cells into induced pluripotent stem cells (iPSCs) offers a unique opportunity to study many aspects of POI from cell differentiation in vitro that could ultimately lead to novel drug development and testing to help treat the disorder. The fibroblasts from POI patients, including fragile X syndrome, abnormal karyotype (45, X; 45, X/46, XX; 45, XO and 47, XXX), and the gene mutation (FIGLA and GDF9) were reprogrammed to pluripotency status by retroviral transduction using defined factors. The morphology, growth characteristics, gene expression profiles, epigenetic status, and in vitro and in vivo differentiation potential of the POI-1-iPSCs (from fragile X syndrome) were analyzed. Then, POI-1-iPSCs were induced to differentiation into primordial germ cells (PGCs) with DNA methyltransferase inhibitors. The iPSCs were successfully generated from POI patients' fibroblasts. The formed iPS clones have the same characteristics of human ESCs. POI-1-iPSCs were successfully generated with germline competence. The POI-1-iPSCs, with genotypes of fragile X syndrome, can be induced to differentiation into PGCs with high efficiency under our culture system by DNA demethylation. This study proved that disease-specific iPSC lines derived from POI patients could be generated and successfully differentiated into PGCs. We established some novel, systemic cell models for the studying of the pathogenesis of POI patients. Second, DNA demethylation may accelerate the induction of human PGCs from iPSCs in vitro and the conclusion needs further exploration. This represents an important step in the novel approach for the study of the pathophysiology and potential egg resource for POI patients.
机译:过早的卵巢不足(POI)是生殖妇女的常见疾病。 Poi的发病机制尚不清楚,虽然已知它涉及卵母细胞分化和发育的病症。将重编程的人体细胞引入诱导的多能干细胞(IPSC)提供了独特的机会,可以研究从体外细胞分化的POI的许多方面,最终可能最终导致新的药物开发和测试,以帮助治疗疾病。 POI患者的成纤维细胞,包括易碎X综合征,核型异常(45,x; 45,x / 46,xx; 45,XO和47,XXX)和基因突变(FIGLA和GDF9)被重新编程为多能性状态使用定义因素进行逆转录病毒转导。分析了POI-1-IPSCS(来自易碎X综合征)的形态,生长特征,基因表达谱,表达状态和体外和体内分化潜力。然后,诱导POI-1-IPSC与DNA甲基转移酶抑制剂的原始生殖细胞(PGC)分化。 IPSCS已从Poi患者的成纤维细胞成功生成。形成的IPS克隆具有相同的人体ESC的特征。 POI-1-IPSCS以种系能力成功生成。 POI-1-IPSCs,具有易碎X综合征的基因型,可以诱导在我们的培养系统下通过DNA去甲基化分化为PGCs。本研究证明,可以生成衍生自POI患者的疾病特异性IPSC线,并成功地分化为PGC。我们建立了一些新的全身细胞模型,用于研究POI患者的发病机制。其次,DNA去甲基化可以在体外加速人类PGC的诱导,结论需要进一步探索。这代表了POI患者病理生理学和潜在蛋资源研究的新方法的重要一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号